Wave Life Sciences Ltd (NASDAQ:WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately $100 million gross proceeds. In addition ...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

CAMBRIDGE, Mass. and LONDON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people ...

Genetics help determine what makes you YOU. Genetics can also impact your health, including your risk for developing certain cancers. Because parents pass their genes on to their children, some ...

Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency, a disease that impacts the ...